Renal artery stenosis overview: Difference between revisions

Jump to navigation Jump to search
Shivam Singla (talk | contribs)
Shivam Singla (talk | contribs)
Line 62: Line 62:


* The invasive diagnostic technique, such as renal angiography, is considered the gold standard for diagnosis and may be used when  
* The invasive diagnostic technique, such as renal angiography, is considered the gold standard for diagnosis and may be used when  
** Concomitant catheterizations are needed or when previously performed non-invasive techniques yielded equivocal results.
* Concomitant catheterizations are needed or when previously performed non-invasive techniques yielded equivocal results.


==Treatment==
==Treatment==

Revision as of 19:17, 15 December 2020

Renal artery stenosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Renal artery stenosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Renal artery stenosis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal artery stenosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal artery stenosis overview

CDC on Renal artery stenosis overview

Renal artery stenosis overview in the news

Blogs on Renal artery stenosis overview

Directions to Hospitals Treating Renal artery stenosis

Risk calculators and risk factors for Renal artery stenosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shivam Singla, M.D.[2]

Overview

  • Renal artery stenosis (RAS) is defined as the unilateral or bilateral progressive narrowing of the renal arteries or their proximal branches of more than 50% in diameter.
  • RAS is a heterogeneous group of diseases that most commonly include: fibromuscular dysplasia (FMD) and atherosclerotic renal artery stenosis (ARAS).
  • Although renal artery stenosis may be an isolated asymptomatic condition,
    • It may commonly lead to secondary hypertension that is thus called renovascular hypertension (RVHT), ischemic nephropathy, and chronic renal insufficiency.
  • Approximately 90% of renal artery stenosis cases occur due to progressive atherosclerosis.
  • The ostium and proximal third of the renal arteries are the most commonly involved regions in atherosclerosis.
  • Segmental and diffuse atherosclerosis may still be seen in the minority of patients, especially in context of chronic kidney disease and poor renal survival.

Pathophysiology

  • The main pathophysiological mechanism behind renal artery stenosis is reduction in renal blood flow
  • Secondary to renal artery stenosis which stimulates renin release from the juxtaglomerular apparatus through activation of the tubuloglomerular feedback, baroreceptor reflex, and the sympathetic nervous system.
  • Elevated angiotensin II activities in turn cause elevation of the arterial pressure and other effects including aldosterone secretion, sodium retention, and left ventricular hypertrophy and remodeling.

Causes

  • Renal artery stenosis is most commonly caused by the development of atherosclerotic plaque in the renal arteries (termed atherosclerotic renal artery stenosis).
  • Less frequently, it is caused by fibromuscular dysplasia.

Classification

  • Renal artery stenosis may be classified according to whether there is unilateral or bilateral involvement of the renal arteries.
  • Additionally, renal artery stenosis is classified anatomically according to the severity of luminal narrowing.
  • The following criteria are used according to most published studies about ARAS.
  • To note, some studies have different classification criteria than those listed above, with "mild disease" starting after 50% of luminal narrowing. Such classification remains coherent with the definition of ARAS as narrowing > 50%.
  • Another classification is based on hemodynamic function in RAS. This classification simply differentiates between hemodynamically insignificant RAS (< 75% stenosis) and hemodynamically significant RAS (> 75% stenosis).

Epidemiology and Demographics

  • Atherosclerotic renal artery stenosis (ARAS) is considered a disease of the elderly.
  • The true prevalence of ARAS has not been reliably determined and prevalence rates present so far may in fact be an underestimate or an overestimate of the true prevalence due to the varying selection criteria in different studies.
  • The prevalence of ARAS increases substantially among patients with cardiovascular co-morbidities, such as diabetes mellitus, dyslipidemia, essential hypertension, and known coronary or peripheral artery disease.

Risk Factors

  • Risk factors for ARAS, per se, are poorly studied. The most commonly associated risk factors are:
    • Atherosclerosis,
    • Advanced age
    • Dyslipidemia
    • Diabetes mellitus
    • Smoking
    • Hypertension.

Diagnosis

  • Non-invasive diagnosis is the first line for the screening of ARAS.
  • Doppler ultrasonography, CTA, and MRA may all be used to diagnose ARAS.
  • The invasive diagnostic technique, such as renal angiography, is considered the gold standard for diagnosis and may be used when
  • Concomitant catheterizations are needed or when previously performed non-invasive techniques yielded equivocal results.

Treatment

Medical therapy is considered the first line of management for patients with ARAS.

Several anti-hypertensive medications have proven to be efficacious in ARAS patients.

According to the 2013 ACC/AHA Guidelines for the Management of PAD, ACE-I and CCB may be used in patients with RAS because they have an effect on both lowering BP and delaying the renal disease.

Other blood pressure-lowering medications include beta-blockers, hydrazine, and chlorothiazide.

Although ARBs may be used as well, they still have level B evidence for use in ARAS because trials have not been conducted on the use of ARBs in such patients.

Angioplasty and stent implantation were previously recommended by the 2013 ACC/AHA Guidelines. However, emerging data from the CORAL trial showed that although there are high technical success rates with angioplasty/stenting, the clinical endpoints are inconsistently and modestly modified. Therefore, raising the suspicion that PRI (percutaneous renal interventions) can incur substantial costs without a significant public health advantage

Vascular reconstruction of the renal arteries may be indicated in a small minority of patients. However, surgical reconstruction is associated with complications and carries a 5-15% for surgical re-intervention.

Case Studies

Related Chapters

External Links

References